Pre-made Ipilimumab benchmark antibody ( Whole mAb, anti-CTLA4/CTLA-4 therapeutic antibody, Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-277

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-277 Category Tag

Product Details

Pre-Made Ipilimumab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

Products Name (INN Index)

Pre-Made Ipilimumab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody

INN Name

Ipilimumab

Target

CTLA4

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

Active

100% SI Structure

5tru:HL:hl/5xj3:AB:DE:JK:GH/6jc2:HL

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2005

Companies

Aduro BioTech,AIO Studien gGmbH,Australian and New Zealand Urogenital and Prostate Cancer Group,Bavarian Nordic,Big Ten Cancer Research Consortium,BioGene Pharmaceutical,Bristol-Myers Squibb,Canadian

Conditions Approved

Malignant melanoma,Renal cell carcinoma

Conditions Active

Colorectal cancer,Non-small cell lung cancer,Gastric cancer,Glioblastoma,Head and neck cancer,Mesothelioma,Oesophageal cancer,Prostate cancer,Small cell lung cancer,Urogenital cancer,Adrenocortical c

Conditions Discontinued

HIV infections,Lymphoma

Development Tech

Medarex UltiMAb Mouse

Previous Name

NA

Gm Offical Target Name

CTLA4

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide